76% of Surveyed Adults Take Supplements Regularly. Clinicians Say the Cocktail Approach Is Landing People in Clinics with Liver and Kidney Damage.

Since this outlet's June 19 coverage of clinicians warning about supplement-driven liver and kidney damage, and June 20 report confirming the FDA conducts no pre-market safety review of supplements, a BBC health report published this weekend puts consumer numbers to the problem.

A survey by the UK consumer group Which?, cited by BBC News, found that 76% of respondents take at least one supplement regularly. The category includes vitamins, minerals, omega-3, probiotics, and herbal supplements. Nearly one in five take four or more every single day.

Those numbers help explain what clinicians have been describing for months: the pipeline of multi-supplement users is enormous, and even a small percentage of adverse reactions at that scale generates a substantial clinical burden.

The Cocktail Problem, in Plain Terms

The concern has never been about single, targeted supplements with a documented deficiency behind them. Vitamin D for someone with confirmed low levels. Iron for someone with anemia. That use is medically straightforward.

The problem clinicians keep flagging is the cocktail approach: stacking creatine, magnesium, collagen, greens powders, herbal blends, and perimenopause tablets simultaneously, often based on social media recommendations rather than a blood test or a doctor's visit.

One nutritionist quoted by BBC News called the volume of supplements people now use "insane." Her concern: "Some are beginning to think that taking a pill is better than eating food. It is not."

The supplement industry does not market deficiency correction. It markets optimization, and the marketing works. The BBC reporter noted she had accumulated creatine, vitamin D, magnesium, collagen, a greens supplement, and a perimenopause blend in her own cupboard without consciously deciding to become a supplement user.

The Regulatory Gap Has Not Closed

As this outlet reported on June 20, the FDA does not require pre-market safety or efficacy review for dietary supplements. A manufacturer can put a product on the shelf without proving it is safe in isolation, let alone in combination with five other products a consumer might be taking simultaneously.

That gap is especially acute for combination effects. A supplement that clears individual safety review, in the rare cases where any review happens at all, tells you nothing about what it does to liver enzyme levels when stacked with three herbal products and a fat-soluble vitamin taken at high doses.

The Strongest Counterargument

The supplement industry and its defenders make a legitimate point: the vast majority of people who take supplements experience no measurable harm, and personal autonomy over one's own health choices is a real value. Restricting supplement access through heavy pre-market regulation could price out or slow access to products that genuinely help people, particularly in communities where dietary gaps are real and healthcare access is limited. Critics of tighter regulation also argue that adverse event reports are rare relative to the hundreds of millions of supplement doses consumed annually.

That concern is worth considering directly. But the counterpoint stands: "rare relative to doses consumed" is cold comfort when the absolute number of liver injury cases is rising, when no pre-market combination-safety data exists, and when consumers have no reliable way to know which stacks carry risk. Rarity and detectability are two different things, and a system with no pre-market review and a voluntary adverse event reporting mechanism is structurally designed to undercount harm.

What Comes Next

The BBC report includes a patient account from Ginger Smith, who believed her supplement regimen was helping her until her health deteriorated. Her specifics are not fully detailed in the available source text, but the pattern matches what U.S. clinicians have described in prior coverage: gradual escalation, no single product as an obvious culprit, delayed recognition that the supplement stack was the variable that changed.

As of June 20, 2026, a straightforward question remains unresolved: the FDA has acknowledged no pre-market review occurs, adverse liver cases are documented, and consumer usage is at scale. What, specifically, does the agency plan to do about combination-product safety guidance, and on what timeline? That question has not been answered in any of the sources reviewed across this reporting arc.